PATENT CLAIM ANALYSIS

Application Number: 15884221
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["435", "006100"]

Abstract:
A method for predicting the responsiveness of a patient having a hematological cancer to a treatment compound, comprising obtaining a biological sample from the patient having the hematological cancer; determining the expression level of one, two, three, four, five, or more genes; and comparing the expression level of the one, two, three, four, five, or more genes in the biological sample with a reference expression level of the same genes, wherein the treatment compound is 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (lenalidomide), 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione (Compound A), or a stereoisomer, pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or a polymorph thereof.

Claim (Index 52):
A method for predicting the responsiveness of a patient having a hematological cancer to a treatment compound, comprising:\n (a) obtaining a biological sample from the patient having the hematological cancer; (b) determining the expression level of one, two, three, four, five, or more of the genes selected from the groups consisting of:\n (i) BICC1, C10orf54, C1RL, C20orf112, C8orf4, CCDC88C, CD97, CEBPB, CFB, CHRDL1, CIRH1A, CPSF3, CSF1R, DDR2, DLGAP5, DUSP1, EMR2, EPB41L3, FBXO32, GAS2L1, GINS4, IFITM2, KCNMB1, LGALS3BP, LRP11, MEGF6, MEIS1, MYO1F, PDGFC, PRNP, PTPRM, RAB31, RBBP8, RUVBL1, SEMA3C, SERPING1, SMOC2, SNRPD1, TBC1D2B, THEMIS2, TMEM173, TPSAB1, TRIP13, TXNIP, ULK1, WDR12, WWTR1, XAF1, ZNF215, \n (ii) ALKBH2, AOAH, C10orf54, C1RL, C8orf4, CD84, CD97, CDC20, CEBPB, CEBPD, CHRDL1, CIRH1A, CPSF3, CYP1B1, FBXO32, FOSL2, GAS2L1, GBP3, GINS4, GNAQ, GPR155, GPRIN3, HJURP, KCNMB1, LRP11, MAFB, MEGF6, MEIS1, MYO1F, MYOF, PCSK5, PDGFC, PHACTR2, PTPRM, RAB31, RALGDS, RUVBL1, SASH1, SERPING1, SMOC2, SNRPD1, SSH1, TBC1D2B, TMEM173, TP53INP2, TRIP13, ULK1, WWTR1, XAF1, ZNF215, \n (iii) C10orf54, C1RL, C20orf112, C8orf4, CCDC88C, CILP, CIRH1A, CLU, CPVL, CSF1R, CTSB, EPB41L3, FBXO32, IFI44, LRP11, MEGF6, MEIS1, PLAT, SERPING1, SPC25, THEMIS2, TPSAB1, ULK1, XAF1, ZNF215, and/or \n (iv) C10orf54, C1RL, C20orf112, C8orf4, CCNB1, CDC6, CILP, CLU, CPSF3, CPVL, CSF1R, CTSB, EPB41L3, FBXO32, IFI44, MEIS1, PHACTR2, PLAT, RUVBL1, SERPING1, SNRPD1, TRIP13, XAF1, ZNF215; and \n (c) comparing the expression level of the one, two, three, four, five, or more of the genes selected from the groups consisting of:\n (i) BICC1, C10orf54, C1RL, C20orf112, C8orf4, CCDC88C, CD97, CEBPB, CFB, CHRDL1, CIRH1A, CPSF3, CSF1R, DDR2, DLGAP5, DUSP1, EMR2, EPB41L3, FBXO32, GAS2L1, GINS4, IFITM2, KCNMB1, LGALS3BP, LRP11, MEGF6, MEIS1, MYO1F, PDGFC, PRNP, PTPRM, RAB31, RBBP8, RUVBL1, SEMA3C, SERPING1, SMOC2, SNRPD1, TBC1D2B, THEMIS2, TMEM173, TPSAB1, TRIP13, TXNIP, ULK1, WDR12, WWTR1, XAF1, ZNF215, \n (ii) ALKBH2, AOAH, C10orf54, C1RL, C8orf4, CD84, CD97, CDC20, CEBPB, CEBPD, CHRDL1, CIRH1A, CPSF3, CYP1B1, FBXO32, FOSL2, GAS2L1, GBP3, GINS4, GNAQ, GPR155, GPRIN3, HJURP, KCNMB1, LRP11, MAFB, MEGF6, MEIS1, MYO1F, MYOF, PCSK5, PDGFC, PHACTR2, PTPRM, RAB31, RALGDS, RUVBL1, SASH1, SERPING1, SMOC2, SNRPD1, SSH1, TBC1D2B, TMEM173, TP53INP2, TRIP13, ULK1, WWTR1, XAF1, ZNF215, \n (iii) C10orf54, C1RL, C20orf112, C8orf4, CCDC88C, CILP, CIRH1A, CLU, CPVL, CSF1R, CTSB, EPB41L3, FBXO32, IFI44, LRP11, MEGF6, MEIS1, PLAT, SERPING1, SPC25, THEMIS2, TPSAB1, ULK1, XAF1, ZNF215, and/or \n (iv) C10orf54, C1RL, C20orf112, C8orf4, CCNB1, CDC6, CILP, CLU, CPSF3, CPVL, CSF1R, CTSB, EPB41L3, FBXO32, IFI44, MEIS1, PHACTR2, PLAT, RUVBL1, SERPING1, SNRPD1, TRIP13, XAF1, ZNF215 \n in the biological sample with a reference expression level of the same genes; wherein the differential expression level of the one, two, three, four, five, or more of the genes in the biological sample relative to the reference expression level of the one, two, three, four, five, or more of the genes indicates that the first patient will be responsive to the treatment compound; and wherein the treatment compound is 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (lenalidomide), 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione (Compound A), or a stereoisomer, pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or a polymorph thereof.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 86.0
- Lexical Diversity: 2.15
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15273205', '13459005', '15150227', '14381004', '13417088']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.558786873403755
- 35 USC 102 Novelty (BERT): 0.5960934871232748
- Combined Prediction Score: 0.562517534775707
- Mean Citation Score: 308.514826
- Max Citation Score: 598.8112
- Similarity Product: 426.47236456317904

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test